ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2266

Outcome of Renal Transplantation in Lupus Patients with Positive and Negative Serology: Survival of the Graft and Patients After Transplant

Zahi Touma1, Murray B. Urowitz2, Dominique Ibanez2 and D. D. Gladman3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Renal disease, systemic lupus erythematosus (SLE) and transplantation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Lupus nephritis (LN) occurs in 50-75% of adults with SLE and up to 20% of LN patients may advance to end stage renal disease over a 10-year period.  The aims of this study were to provide an overview of the characteristics of lupus patients with renal transplantation (RT) followed in the Lupus Clinic between 1970-2012, and to determine the survival of the graft and patients after RT.

Methods:

Patients with lupus have been followed prospectively at the lupus clinic since 1970. Patients attend the clinic at 2-6 month intervals and the standard protocol includes: complete history, physical and laboratory evaluation. Patients who underwent RT were identified from the database. RT outcomes included: a) nonfunctional graft requiring dialysis within ≤3 weeks, b) graft failure requiring permanent dialysis after 3 weeks, c) graft survival not requiring dialysis and d) death.

Descriptive analysis was used to study the characteristics of all patients. We grouped the patients into graft failure and graft survival. The duration of graft failure was defined as the time between RT and subsequent permanent dialysis. The duration of graft survival was defined as the time between RT and recipient death or the end of the study with functioning graft.

 

Results:

25 (20 F) of 1645 patients followed in the lupus cohort and of 780 with renal involvement were identified with RT. 10 (40%) were Caucasian, 7 (28%) Black, 4 (16%) Asian and 4 (16%) others. The age at diagnosis of lupus and at transplant was 30.7±13.8 and 38.1±9.6 years respectively. Lupus duration at RT was 13.3±7.6 years.  2 (8%) patients had a nonfunctional graft, 4 (16%) patients had graft failure (1 patient had failure <5 years and 3 ≥5 years) and 19 (76%) patients had graft survival (8 had S ≥5 years) (Table 1). Patients with graft survival were older and had longer lupus duration compared to patients with failure at the time of RT. 25% of the graft failures had positive lupus serology compared to 47% in the graft survival 1 year prior to RT.

The time to graft failure (n=4) was 5.75±4.99y. In the failure group 3 patients died by 6±5.19 years and one patient is still alive. In the graft survival group 3 patients died by 5.6±4.6 years and one patient was lost of follow-up. Cause of death was not related to renal disease in 2patients and unknown in one patient.

Conclusion:

25 of 780 lupus nephritis patients followed at the Lupus Clinic underwent RT.   The persistence of serological abnormalities at the time of RT was not associated with graft failure.

            

Table 1. Characteristics if graft failure and graft survival patients.

 

Graft Failure

N=4

Graft survival

N=19

Sex

F 75%

F 84%

Age at lupus diagnosis

25.4±7.3

24.4±8.3

Age at transplant

29.8±9.1

40.0±9.5

Lupus duration at 1st clinic visit

5.9±4.0

7.2±7.8

Lupus duration at transplant

4.5±2.1

15.5±7.1

Ethnicity

                       Caucasian

                       Black

                       Asian

                       Others

 

1

1

2

0

 

7

6

2

4

Positive DNA in 1 year prior

1/4

5/18

Low complements in 1 year prior

1/4

9/19

Positive DNA and/or low complements in 1 year prior

1/4

9/19

Positive DNA and/or low complements in 1 year after transplant

2/3

8/19

SDI at transplant

4.0±0 (n=4)

4.6±1.9 (n=17)

Time (duration) on dialysis prior to transplant

3.9±2.4 (n=4)

5.8±5.6 (n=6)

 


Disclosure:

Z. Touma,
None;

M. B. Urowitz,
None;

D. Ibanez,
None;

D. D. Gladman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcome-of-renal-transplantation-in-lupus-patients-with-positive-and-negative-serology-survival-of-the-graft-and-patients-after-transplant/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology